Harvard BioscienceHBIO
13F holders, Q2 2026 (June 30)2holders −1
0new positions
0sold out
$6.15avg. 13F price*
At the end of Q2 2026, 2 institutions reported holding Harvard Bioscience Inc. (HBIO) in their 13F filings, down 1 from Q1 2026. 0 opened new positions and 0 sold out. The largest holders were Meros Investment Management, LP ($1.1M) and Nano Cap New Millennium Growth Fund L P ($880K).
- Company
- Harvard Bioscience Inc.
- CUSIP
- 416906105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2026 → Q2 2026: 90,052 shares bought, net +90,052 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Meros Investment Management, LP | 0.36% | Add +54.4% | 182,992 | $1.1M |
| Nano Cap New Millennium Growth Fund L P | 0.68% | Add +21.8% | 143,082 | $880K |
"% of holder's portfolio" is HBIO's weight in each manager's 13F, not the share of Harvard Bioscience Inc. the manager owns.